Global Medicines Regulation in Pregnancy and Lactation: Addressing Emerging Therapies, Safety, and Access Inequalities
DOI:
https://doi.org/10.14738/bjhr.1206.19640Keywords:
Pregnancy, Lactation, Drug Safety, Regulatory Frameworks, Pharmacovigilance, Emerging Therapies, Access InequalitiesAbstract
Safe medication use during pregnancy and lactation is fundamental to protecting maternal and neonatal health. However, global variability in regulatory frameworks, pharmacovigilance systems, and access to therapies presents major challenges-particularly for emerging treatments such as biologics, GLP-1 receptor agonists, and novel small molecules. This review aimed to synthesize international regulatory frameworks, evaluate safety monitoring practices, and explore disparities in access to medicines for pregnant and lactating populations. A narrative review was conducted using PubMed, Embase, Scopus, Web of Science, and regulatory agency websites (FDA, EMA, Health Canada, MHLW Japan, WHO), supplemented by pharmacovigilance databases (FAERS, VigiBase, EudraVigilance). Publications in English from 2000-2025 addressing regulatory policies, safety monitoring, or access inequalities were included. Extracted data were analyzed to identify global trends, gaps, and best practices in maternal-fetal pharmacotherapy. High-income countries demonstrate mature systems, including the FDA Pregnancy and Lactation Labeling Rule, EMA risk management plans, and comprehensive pharmacovigilance infrastructures. In contrast, low- and middle-income countries (LMICs) often face fragmented regulations, limited monitoring capacity, and restricted access to innovative therapies. Global initiatives such as the World Health Organization (WHO) guidelines, the International Council for Harmonization (ICH) E11(R1) guideline, and TransCelerate programs promote harmonization, yet substantial gaps remain. Active and passive surveillance mechanisms, pregnancy registries, and real-world data enhance safety assessment for emerging therapies, while access inequalities persist due to regulatory delays, cost, and sociocultural barriers. Despite meaningful advances in high-resource settings, LMICs continue to experience major challenges in ensuring safe and equitable access to medicines. Strengthening evidence-based, harmonized regulatory frameworks, expanding pharmacovigilance coverage, and integrating real-world evidence are essential to safeguarding maternal and neonatal health. Coordinated global collaboration is imperative to achieve equitable access to innovative therapies worldwide.
References
C. M. Wittich, C. M. Burkle, and W. L. Lanier, “Ten common questions (and their answers) about off-label drug use,” Mayo Clin. Proc., vol. 87, no. 10, pp. 982–990, 2012, doi: 10.1016/j.mayocp.2012.04.017.
M. Mei, H. Xu, L. Wang, G. Huang, Y. Gui, and X. Zhang, “Current practice and awareness of pediatric offlabel drug use in Shanghai, China-a questionnaire-based study,” BMC Pediatr., vol. 19, no. 1, pp. 1–7, 2019, doi: 10.1186/s12887-019-1664-7.
M. Drenska, E. Naseva, and I. Getov, “Physician’s knowledge and experience with the off-label use of medicines,” Biotechnol. Biotechnol. Equip., vol. 35, no. 1, pp. 111–116, 2021, doi: 10.1080/13102818.2020.1856718.
D. Alyami, A. A. Alyami, A. Alhossan, and M. Salah, “Awareness and Views of Pharmacists and Physicians Toward Prescribing of Drugs for Off-Label Use in the Pediatric Population in Saudi Arabia,” Cureus, vol. 14, no. 3, pp. 11–14, 2022, doi: 10.7759/cureus.23082.
S. Conroy et al., “Survey of unlicensed and off label drug use in paediatric wards in European countries,” Br. Med. J., vol. 320, no. 7227, pp. 79–82, Jan. 2000, doi: 10.1136/BMJ.320.7227.79.
D. Zanon et al., “Off-label prescribing patterns of antiemetics in children: A multicenter study in Italy,” Eur. J. Pediatr., vol. 172, no. 3, pp. 361–367, Mar. 2013, doi: 10.1007/S00431-012-1894-2.
C. Pandolfini and M. Bonati, “A literature review on off-label drug use in children,” Eur. J. Pediatr., vol. 164, no. 9, pp. 552–558, Aug. 2005, doi: 10.1007/S00431-005-1698-8.
J. Emmerich, N. Dumarcet, and A. Lorence, “France’s new framework for regulating off-label drug use,” N. Engl. J. Med., vol. 367, no. 14, pp. 1279–1281, Oct. 2012, doi: 10.1056/NEJMP1208347.
J. K. Aronson and R. E. Ferner, “Unlicensed and off-label uses of medicines: definitions and clarification of terminology,” Br. J. Clin. Pharmacol., vol. 83, no. 12, pp. 2615–2625, 2017, doi: 10.1111/bcp.13394.
K. A. Neville et al., “Off-label use of drugs in children,” Pediatrics, vol. 133, no. 3, pp. 563–567, 2014, doi: 10.1542/PEDS.2013-4060.
C. Lee Ventola, “Off-label drug information: Regulation, distribution, evaluation, and related controversies,” P T, vol. 34, no. 8, 2009.
A. S. Kesselheim, S. Woloshin, Z. Lu, F. A. Tessema, K. M. Ross, and L. M. Schwartz, “Physicians’ Perspectives on FDA Approval Standards and Off-label Drug Marketing,” JAMA Intern. Med., vol. 179, no. 5, pp. 707–709, May 2019, doi: 10.1001/JAMAINTERNMED.2018.8121.
N. Ghinea, I. Kerridge, M. Little, and W. Lipworth, “Challenges to the validity of using medicine labels to categorize clinical behavior: An empirical and normative critique of ‘off-label’ prescribing,” J. Eval. Clin. Pract., vol. 23, no. 3, pp. 574–581, Jun. 2017, doi: 10.1111/JEP.12673.
“EudraLex - Volume 1 - European Commission.”
“CRS Search Results.”
“Federal Register :: Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers; Revised Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request.”
S. A. Berns, E. S. Bulgakova, D. O. Orlov, and I. A. Belkin, “Assessment of Awareness and Experience of Using off-label Drugs by Doctors of Clinical Specialties,” Kardiologiya, vol. 61, no. 5, pp. 41–50, 2021, doi: 10.18087/CARDIO.2021.5.N1510.
W. F. Friedman, M. J. Hirschklau, M. P. Printz, P. T. Pitlick, and S. E. Kirkpatrick, “Pharmacologic closure of patent ductus arteriosus in the premature infant,” N. Engl. J. Med., vol. 295, no. 10, pp. 526–529, Sep. 1976, doi: 10.1056/NEJM197609022951003.
M. E. Schram, R. J. Borgonjen, C. M. J. M. Bik, J. G. Van Der Schroeff, J. J. E. Van Everdingen, and P. I. Spuls, “Off-label use of azathioprine in dermatology: a systematic review,” Arch. Dermatol., vol. 147, no. 4, pp. 474–488, Apr. 2011, doi: 10.1001/ARCHDERMATOL.2011.79.
S. Berthet, B. Charpiat, and J. Y. Mabrut, “Erythromycin as a prokinetic agent: risk factors,” J. Visc. Surg., vol. 147, no. 2, 2010, doi: 10.1016/J.JVISCSURG.2010.06.001.
G. A. Kerchner, M. C. Tartaglia, and A. L. Boxer, “Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia,” Expert Rev. Neurother., vol. 11, no. 5, pp. 709–717, May 2011, doi: 10.1586/ERN.11.6.
A. Atia, “Pharmacovigilance in Libya: Current Status and Future Trends,” Indian J. Pharm. Pract., vol. 12, no. 4, pp. 267–269, Sep. 2019, doi: 10.5530/IJOPP.12.4.56.
S. M. Price, A. C. O’Donoghue, L. Rizzo, S. Sapru, and K. J. Aikin, “What influences healthcare providers’ prescribing decisions? Results from a national survey,” Res. Social Adm. Pharm., vol. 17, no. 10, pp. 1770–1779, Oct. 2021, doi: 10.1016/J.SAPHARM.2021.01.012.
R. Basak and D. J. McCaffrey, “Hospital pharmacists’ perceived beliefs and responsibilities in indicationbased off-label prescribing,” Int. J. Clin. Pharm., vol. 40, no. 1, pp. 36–40, Feb. 2018, doi: 10.1007/S11096-017-0567-7/METRICS.
G. Mudur, “Indian Medical Association wants off-label prescribing,” BMJ Br. Med. J., vol. 328, no. 7446, p. 974, 2004, doi: 10.1136/BMJ.328.7446.974-C.
J. E. Raubenheimer, P. H. Myburgh, and A. S. Bhagavathula, “Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface,” BMC Glob. public Heal., vol. 2, no. 1, p. 63, Sep. 2024, doi: 10.1186/S44263-024-00095-W.
“Trulicity & Weight Loss | HCP | Trulicity (dulaglutide).”
C. Corcoran and T. F. Jacobs, “Metformin,” Encycl. Biomed. Gerontol. Vol. 1-3, vol. 2, pp. V2-424-V2-432, Aug. 2023, doi: 10.1016/B978-0-12-801238-3.62141-4.
D. C. Radley, S. N. Finkelstein, and R. S. Stafford, “Off-label prescribing among office-based physicians,” Arch. Intern. Med., vol. 166, no. 9, pp. 1021–1026, May 2006, doi: 10.1001/ARCHINTE.166.9.1021.
H. Chen, J. H. Reeves, J. E. Fincham, W. K. Kennedy, J. H. Dorfman, and B. C. Martin, “Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia medicaid enrollees in 2001,” J. Clin. Psychiatry, vol. 67, no. 6, pp. 972–982, 2006, doi: 10.4088/JCP.V67N0615.
H. W. Lin, K. Phan, and S. J. Lin, “Trends in off-label beta-blocker use: a secondary data analysis,” Clin. Ther.,
R. H. Dworkin et al., “Recommendations for the pharmacological management of neuropathic pain: an overview and literature update,” Mayo Clin. Proc., vol. 85, no. 3 Suppl, 2010, doi: 10.4065/MCP.2009.0649.
R. S. Stafford, “Regulating off-label drug use--rethinking the role of the FDA,” N. Engl. J. Med., vol. 358, no. 14, pp. 1427–1429, Apr. 2008, doi: 10.1056/NEJMP0802107.
S. Ekins-Daukes, P. J. Helms, M. W. Taylor, and J. S. McLay, “Off-label prescribing to children: attitudes and experience of general practitioners,” Br. J. Clin. Pharmacol., vol. 60, no. 2, pp. 145–149, Aug. 2005, doi: 10.1111/J.1365-2125.2005.02397.X. 90 Thomson, W. (2025). The Delusional Addiction & Ignorance Associated with Fitness Regimes. British Journal of Healthcare and Medical Research,
S. K. Gupta and R. P. Nayak, “Off-label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authorities,” J. Pharmacol. Pharmacother., vol. 5, no. 2, pp. 88–92, 2014, doi: 10.4103/0976-500X.130046/ASSET/BE14EA90-8B26-4204-81AA-302023C57AFC/ASSETS/0976-500X.130046.FP.PNG.
K. A. Neville et al., “Off-Label Use of Drugs in Children,” Pediatrics, vol. 133, no. 3, pp. 563–567, Mar. 2014, doi: 10.1542/PEDS.2013-4060.
G. Mudur, “Indian Medical Association wants off-label prescribing,” BMJ, vol. 328, no. 7446, p. 974, Apr. 2004, doi: 10.1136/BMJ.328.7446.974-C.
A. Vijay, J. E. Becker, and J. S. Ross, “Patterns and predictors of off-label prescription of psychiatric drugs,” PLoS One, vol. 13, no. 7, p. e0198363, Jul. 2018, doi: 10.1371/JOURNAL.PONE.0198363.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Riad Mohammed Abdelrahman, Taha Hussein Musa, Ismail Adam Arbab, Mohsen Hussein Suliman, Ala Gamaleldin Khalifa, Eltieb Omer Ahmed, Sahar Ibrahim Gasmallah, Wafaa Ramadan Ahmed, Khalid Hamid Fadul, Mohammed Jalal
This work is licensed under a Creative Commons Attribution 4.0 International License.
